2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.523

Change

0.00 (0.00)%

Market Cap

N/A

Volume

300.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.09 (-0.31%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.21 (-0.41%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.28 (+0.05%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.06 (-0.40%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.61 (-0.56%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.98 (-0.90%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.80 (-0.33%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.06 (+0.77%)

USD 43.12B
0ZC:F Zscaler Inc

+2.50 (+1.39%)

USD 37.92B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.11% 86% B+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.11% 86% B+ 70% C-
Trailing 12 Months  
Capital Gain 9.66% 53% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.66% 49% F 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.21% 13% F 28% F
Dividend Return -5.21% 10% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.54% 54% F 85% B
Risk Adjusted Return -41.56% 18% F 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.